Intensity Therapeutics, Inc. (INTS)
NASDAQ: INTS · Real-Time Price · USD
4.700
-0.050 (-1.05%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Intensity Therapeutics Employees
As of December 31, 2025, Intensity Therapeutics had 7 total employees, including 5 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,527,571
Market Cap
12.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | 0 | - | 5 | 2 |
| Dec 31, 2024 | 7 | 0 | - | 5 | 2 |
| Dec 31, 2023 | 7 | 3 | 75.00% | 5 | 2 |
| Mar 31, 2023 | 4 | -2 | -33.33% | 3 | 1 |
| Jun 30, 2022 | 4 | - | - | 4 | 0 |
| Mar 31, 2022 | 6 | - | - | 5 | 1 |
| Dec 31, 2021 | 6 | - | - | 5 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Senti Biosciences Holdings | 39 |
| Lunai Bioworks | 29 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 18 |
| BioVie | 13 |
| Cocrystal Pharma | 10 |
INTS News
- 5 days ago - Intensity Therapeutics provides update in Invincicle-4 study - TheFly
- 5 days ago - Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PRNewsWire
- 19 days ago - Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 - PRNewsWire
- 4 weeks ago - Intensity Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - PRNewsWire
- 2 months ago - Intensity Therapeutics reports Q1 EPS (96c), consensus ($1.09) - TheFly
- 2 months ago - Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Intensity Therapeutics Quarterly report: Q1 2026 - Filings